Now, it looks like that inside track may pay out in spades:
The editor of Stealth Stocks explains, "Siga is a bio-defense company. In 2004, the U.S. started an initiative called Project BioShield, which gave the government the right to purchase and stockpile vaccines and drugs to fight anthrax, smallpox and other potential agents of bio-terror.
"SIGA is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens and their ST-246 drug is considered to be the only known cure for smallpox, which the government is keenly interested in.
"Recently, BARDA has stated their intent to award SIGA a $500 million contract, with options that potentially could be as high as $2.8 billion in orders.
Half a billion? Options as high as $2.8 billion?
It looks like SIGA's investment in Stern may just be paying off.